Idiopathic Pulmonary Fibrosis Therapeutics Market, Trends, Size, Share, Growth and Forecast to 2022 by P&S Market Research

The global idiopathic pulmonary fibrosis therapeutics market is expected to witness significant growth due to current unmet medical need of pulmonary fibrosis, scarcity of the permanent treatment of the disease, increasing incidence among population across the globe, and high demand for safe and effective medication. The regulatory bodies are supporting the idiopathic pulmonary fibrosis market by providing designations and grants for speeding up the drug development process. In March 2015, Lebrikizumab, a Genentech’s humanized monoclonal antibody drug, received Orphan Drug Designation by U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis.

Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market

The pipeline of idiopathic pulmonary fibrosis is rich, with more than 50 drugs. The pharmaceutical companies are actively involved in the research and development of drug for idiopathic pulmonary fibrosis. Asahi Kasei Pharma Corporation has Thrombomodulin Alfa drug in its Phase III clinical trial for idiopathic pulmonary fibrosis. The drug is already marketed in Japan, under the name of Recomodulin for the treatment of disseminated intravascular coagulation.

Idiopathic pulmonary fibrosis is defined as a chronic, gradually increasing lung disease of unknown cause. The disease primarily involves the interstitium (the tissue and space around the air sacs of the lungs) and it does not directly affect the airways or blood vessels. The lung damage caused by pulmonary fibrosis cannot be repaired; however, medications and therapies can help to ease symptoms and improve quality of life. Management and surgery are the only options to prevent further complications of idiopathic pulmonary fibrosis. The damage caused from the lung scarring cannot be reversed.

Geographically, North America is expected to be the largest market for idiopathic pulmonary fibrosis owing to the large number of research and development activities, high healthcare expenditure, and high incidence of the disease. The U.S. contributed largest revenue to the North American idiopathic pulmonary fibrosis market and it is expected to remain the largest market globally, during the forecast period.

Browse Other Related Report at: https://www.psmarketresearch.com/industry-report/healthcare

Some of the key players operating in the global idiopathic pulmonary fibrosis market are F. Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Merck & Co., Inc., Promedior, Inc., Sanofi, ProMetic Life Sciences Inc., Kadmon Holdings, Inc., MediciNova, Inc., GlaxoSmithKline plc, Biogen Inc., and Celgene Corporation.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com